查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1625205

到 2030 年In Silico临床试验市场预测：按类型、模拟类型、治疗方法、技术、应用、最终用户和地区进行的全球分析

In Silico Clinical Trials Market Forecasts to 2030 - Global Analysis By Type, Simulation Type, Therapeutic, Technology, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 预测，到 2024 年，全球In Silico临床试验市场规模将达到 36 亿美元，预计在预测期内复合年增长率为 8.4%，到 2000 年将达到 58 亿美元。

In Silico临床试验使用电脑模拟和建模来重建人类生物学并预测医疗干预措施的有效性。这些虚拟试验使用大量患者资料、生物模型和计算演算法来模拟药物、治疗方法或设备在现实临床环境中的工作方式。透过取代或减少对传统体内测试的需求，电脑模拟测试提供了一种更快、更具成本效益的方法，可以在临床引入之前评估治疗的安全性和有效性，并提供合乎道德的替代方案。

根据欧洲药品管理局（欧盟）统计，欧盟/欧洲经济区每年批准超过 4,000 项临床试验，其中 60% 由製药公司赞助，40% 由非商业赞助商赞助。印度临床试验註册中心 (CTRI) 的数据显示，2021 年印度核准了100 多项国际临床试验，这是自 2013 年以来的最高数量。

对更安全药物的需求不断增长

市场开发对更安全药物的需求不断增长，这是由于对更高效、更具成本效益和合乎道德的药物开发流程的需求所推动的。In Silico，使用先进的计算模型，透过在实际临床试验之前预测药物疗效、毒性和患者反应，为传统临床试验提供更安全的替代方案。这种方法可以加快药物核准速度，降低风险，最大限度地减少对动物和人体测试的依赖，并满足监管和公共卫生目标。

难以获得高品质资料

市场上高品质资料的有限性阻碍了预测模型的准确性和可靠性。资料不足或偏差可能会为模拟带来缺陷，从而导致对药物疗效、安全性和患者反应的错误预测。这削弱了In Silico临床试验取代传统方法的潜力，减缓了药物开发，增加了风险，并可能导致监管部门核准延迟或不批准新治疗方法。

计算建模和人工智慧的进展

计算建模和人工智慧的发展透过提高药物开发的准确性和效率正在彻底改变市场。人工智慧演算法分析大量资料集来预测药物交互作用、患者反应和潜在副作用。改进的计算模型可以模拟复杂的生物系统并减少对传统临床试验的依赖。这些创新可以实现更快、更准确的药物测试，优化临床结果和安全性，同时降低成本并加快新疗法的上市时间。

监管和道德的不确定性

市场中的监管和道德不确定性对采用提出了重大挑战。药物测试中计算模型的使用缺乏明确的指南可能会延迟核准过程并增加合规风险。此外，有关资料隐私、病患同意和模型透明度的伦理问题可能会阻碍人们对这些技术的信心，减缓进展，并限制其取代传统临床试验方法的潜力。

COVID-19 的影响：

COVID-19 大流行凸显了对更快、更有效的药物开发方法的需求，并加速了In Silico临床试验的采用。由于传统的临床试验面临中断，计算模型对于快速药物测试和疫苗开发变得至关重要。这次疫情凸显了虚拟模拟在减少临床试验时间、成本和对物理互动的依赖方面的优势，刺激了市场的进一步投资和创新。

预计临床前测试领域在预测期内将是最大的。

预计临床前测试领域将在预测期内占据最大的市场占有率。这些虚拟试验使研究人员能够预测药物功效、安全性和药物动力学，并帮助识别潜在风险、副作用和最佳剂量。透过利用人工智慧、机器学习和其他预测技术，In Silico临床前测试可以减少与传统动物和人体测试相关的成本、时间和伦理问题，加速药物开发并提高成功率。

机器学习领域预计在预测期内复合年增长率最高

预计机器学习领域在预测期内将表现出最高的复合年增长率。这些演算法处理大量资料集来预测患者反应、确定最佳剂量策略并模拟试验结果，从而显着缩短时间。该技术还将增强决策、提高测试准确性并支援个人化医疗。因此，机器学习正成为加速药物开发和推动更有效率、资料主导的临床研究方法的重要工具。

比最大的地区

由于计算建模、人工智慧和巨量资料分析的进步，预计北美地区在预测期内将占据最大的市场占有率。这些虚拟模拟透过提高效率、降低成本和最小化风险，正在彻底改变药物开发。监管接受度的提高、个人化医疗需求的增加以及对精准医疗保健的日益关注等关键因素正在促进该地区的市场扩张。

复合年增长率最高的地区：

在计算模型进步的推动下，亚太地区预计将在预测期内实现最高成长率。人工智慧 (AI)、机器学习 (ML) 和巨量资料越来越多地融入In Silico临床试验市场。这些技术可以实现更好的预测模型、提高测试准确性并降低开发成本。此外，生物创业公司数量的增加以及政府对医疗保健数位转型的支持也推动了市场成长。

免费客製化服务

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场公司的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争标基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 研究资讯来源
    • 主要研究资讯来源
    • 二次研究资讯来源
    • 先决条件

第三章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 技术分析
  • 应用分析
  • 最终用户分析
  • 新兴市场
  • COVID-19 的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第五章全球In Silico临床试验市场：按类型

  • 临床前测试
  • 临床试验
  • 上市后测试
  • 法规遵从性测试
  • 疾病模型测试
  • 其他类型

第六章全球In Silico临床试验市场：依模拟类型

  • 生理模拟
  • 毒理学模拟
  • 疾病模型
  • 基于群体的模拟
  • 虚拟病人模拟

第七章全球In Silico临床试验市场：依治疗方法

  • 肿瘤学
  • 感染疾病
  • 心臟病学
  • 神经病学
  • 糖尿病
  • 其他治疗方法

第八章全球In Silico临床试验市场：依技术分类

  • 计算生物学
  • 人工智慧
  • 机器学习
  • 系统生物学
  • 其他技术

第九章全球In Silico临床试验市场：依应用分类

  • 药物发现与开发
  • 医疗设备开发
  • 数位健康技术
  • 个人化医疗
  • 其他用途

第 10 章全球In Silico临床试验市场：依最终使用者分类

  • 製药和生物技术公司
  • 学术机构
  • 合约研究组织（CRO）
  • 监管机构
  • 其他最终用户

第十一章全球In Silico临床试验市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东/非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第十二章 主要进展

  • 合约、伙伴关係、合作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务拓展
  • 其他关键策略

第十三章 公司概况

  • Novadiscovery
  • Dassault Systemes
  • GNS Healthcare
  • Clarivate
  • Evotec
  • Abzena Ltd.
  • PerkinElmer Inc.
  • Schrodinger, Inc.
  • Selvita
  • Tracxn Technologies
  • WuXi AppTec
  • Hoffmann-La Roche
  • Mars
  • PYC Therapeutics
  • Immatics
Product Code: SMRC28160

According to Stratistics MRC, the Global In Silico Clinical Trials Market is accounted for $3.6 billion in 2024 and is expected to reach $5.8 billion by 200 growing at a CAGR of 8.4% during the forecast period. In silico clinical trials are the use of computer simulations and modeling to replicate human biology and predict the effects of medical interventions. These virtual trials use vast amounts of patient data, biological models, and computational algorithms to simulate how drugs, therapies, or devices would perform in real-world clinical settings. By replacing or reducing the need for traditional in vivo trials, in silico trials offer a faster, cost-effective, and ethical alternative for evaluating the safety and efficacy of treatments before clinical implementation.

According to the European Medicines Agency - European Union, in the EU / EEA, more than 4,000 clinical trials are authorised each year, of which 60% of clinical trials are sponsored by the pharma industry and 40% by non-commercial sponsors. As per the Clinical Trials Registry India (CTRI), India approved over 100 global clinical trials in 2021, the highest since 2013.

Market Dynamics:

Driver:

Growing demand for safer drugs

The growing demand for safer drugs in the market is driven by the need for more efficient, cost-effective, and ethical drug development processes. In silico trials, using advanced computational models, offer a safer alternative to traditional clinical trials by predicting drug efficacy, toxicity, and patient responses before real-world testing. This approach accelerates drug approval, reduces risks, and minimizes the reliance on animal and human testing, aligning with regulatory and public health goals.

Restraint:

Limited availability of high-quality data

The limited availability of high-quality data in the market hampers the accuracy and reliability of predictive models. Inadequate or biased data can lead to flawed simulations, resulting in incorrect predictions about drug efficacy, safety, or patient responses. This undermines the potential of in silico trials to replace traditional methods, slowing down drug development, increasing risks, and potentially leading to delayed or failed regulatory approvals for new treatments.

Opportunity:

Advances in computational modeling and AI

Advances in computational modeling and AI are revolutionizing market by enhancing the accuracy and efficiency of drug development. AI algorithms analyze vast datasets to predict drug interactions, patient responses, and potential side effects. Improved computational models simulate complex biological systems, reducing reliance on traditional trials. These innovations enable faster, more precise drug testing, optimizing clinical outcomes and safety while lowering costs and accelerating time-to-market for new treatments.

Threat:

Regulatory and ethical uncertainty

Regulatory and ethical uncertainty in the market poses a significant challenge to widespread adoption. The lack of clear guidelines on the use of computational models in drug testing can delay approval processes and increase compliance risks. Additionally, ethical concerns about data privacy, patient consent, and model transparency may hinder trust in these technologies, slowing progress and limiting their potential to replace traditional clinical trial methods effectively.

Covid-19 Impact:

The COVID-19 pandemic accelerated the adoption of In Silico Clinical Trials by highlighting the need for faster, more efficient drug development methods. With traditional trials facing disruptions, computational models became crucial for rapid drug testing and vaccine development. The pandemic emphasized the benefits of virtual simulations in reducing trial timelines, costs, and reliance on physical interactions, driving further investment and innovation in the market.

The preclinical trials segment is expected to be the largest during the forecast period

The preclinical trials segment is expected to account for the largest market share during the projection period. These virtual trials enable researchers to predict drug efficacy, safety, and pharmacokinetics, helping to identify potential risks, side effects, and optimal dosages. By utilizing AI, machine learning, and other predictive technologies, in silico preclinical trials reduce the cost, time, and ethical concerns associated with traditional animal and human studies, accelerating drug development and improving success rates.

The machine learning segment is expected to have the highest CAGR during the forecast period

The machine learning segment is expected to have the highest CAGR during the extrapolated period. These algorithms process vast datasets to predict patient responses, identify optimal dosing strategies, and simulate trial outcomes, significantly reducing the time. This technology also enhances decision-making, improves trial accuracy, and supports personalized medicine. As a result, ML is becoming a crucial tool in accelerating drug development and advancing more efficient, data-driven clinical research methodologies.

Region with largest share:

North America region is projected to account for the largest market share during the forecast period driven by advancements in computational modeling, artificial intelligence, and big data analytics. These virtual simulations are revolutionizing drug development by enhancing efficiency, reducing costs, and minimizing risks. Key factors such as increasing regulatory acceptance, a rising demand for personalized medicine, and a growing focus on precision healthcare contribute to the market's expansion in the region.

Region with highest CAGR:

Asia Pacific is expected to register the highest growth rate over the forecast period driven by advancements in computational models. Artificial Intelligence (AI), Machine Learning (ML), and Big Data are being increasingly integrated into the in silico clinical trials market. These technologies enable better prediction models, improve trial accuracy, and reduce development costs. Additionally, the rise in biotech startups, along with government support for digital transformation in healthcare, is helping the market grow.

Key players in the market

Some of the key players in In Silico Clinical Trials market include Novadiscovery, Dassault Systemes, GNS Healthcare, Clarivate, Evotec, Abzena Ltd., PerkinElmer Inc., Schrodinger, Inc., Selvita, Tracxn Technologies, WuXi AppTec, Hoffmann- La Roche, Mars, PYC Therapeutics and Immatics.

Key Developments:

In October 2024, Dassault Systemes announced the availability of the world's first guide for the medical device industry that outlines how to use virtual twins to accelerate clinical trials. The in silico clinical trial "ENRICHMENT Playbook" marks a significant advancement in the integration of virtual twins into the regulatory process in response to needs for improved patient safety, regulatory compliance, and pace of innovation.

In July 2024, Clarivate Plc announced the launch of its new OFF-X platform. It delivers critical drug and target safety information to proactively identify risks. Integrated with Cortellis Drug Discovery Intelligence(TM), OFF-X(TM) provides a comprehensive, one-stop resource for drug safety information, streamlining processes, increasing efficiencies and delivering a competitive advantage.

Types Covered:

  • Preclinical Trials
  • Clinical Trials
  • Post-Market Trials
  • Regulatory Compliance Trials
  • Disease Modeling Trials
  • Other Types

Simulation Types Covered:

  • Physiological Simulations
  • Toxicology Simulations
  • Disease Models
  • Population-Based Simulations
  • Virtual Patient Simulations

Therapeutics Covered:

  • Oncology
  • Infectious Disease
  • Cardiology
  • Neurology
  • Diabetes
  • Other Therapeutics

Technologies Covered:

  • Computational Biology
  • Artificial Intelligence
  • Machine Learning
  • Systems Biology
  • Other Technologies

Applications Covered:

  • Drug Discovery and Development
  • Medical Device Development
  • Digital Health Technologies
  • Personalized Medicine
  • Other Applications

End Users Covered:

  • Pharmaceutical and Biotechnology Companies
  • Academic Institutions
  • Contract Research Organizations (CROs)
  • Regulatory Authorities
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Technology Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global In Silico Clinical Trials Market, By Type

  • 5.1 Introduction
  • 5.2 Preclinical Trials
  • 5.3 Clinical Trials
  • 5.4 Post-Market Trials
  • 5.5 Regulatory Compliance Trials
  • 5.6 Disease Modeling Trials
  • 5.7 Other Types

6 Global In Silico Clinical Trials Market, By Simulation Type

  • 6.1 Introduction
  • 6.2 Physiological Simulations
  • 6.3 Toxicology Simulations
  • 6.4 Disease Models
  • 6.5 Population-Based Simulations
  • 6.6 Virtual Patient Simulations

7 Global In Silico Clinical Trials Market, By Therapeutic

  • 7.1 Introduction
  • 7.2 Oncology
  • 7.3 Infectious Disease
  • 7.4 Cardiology
  • 7.5 Neurology
  • 7.6 Diabetes
  • 7.7 Other Therapeutics

8 Global In Silico Clinical Trials Market, By Technology

  • 8.1 Introduction
  • 8.2 Computational Biology
  • 8.3 Artificial Intelligence
  • 8.4 Machine Learning
  • 8.5 Systems Biology
  • 8.6 Other Technologies

9 Global In Silico Clinical Trials Market, By Application

  • 9.1 Introduction
  • 9.2 Drug Discovery and Development
  • 9.3 Medical Device Development
  • 9.4 Digital Health Technologies
  • 9.5 Personalized Medicine
  • 9.6 Other Applications

10 Global In Silico Clinical Trials Market, By End User

  • 10.1 Introduction
  • 10.2 Pharmaceutical and Biotechnology Companies
  • 10.3 Academic Institutions
  • 10.4 Contract Research Organizations (CROs)
  • 10.5 Regulatory Authorities
  • 10.6 Other End Users

11 Global In Silico Clinical Trials Market, By Geography

  • 11.1 Introduction
  • 11.2 North America
    • 11.2.1 US
    • 11.2.2 Canada
    • 11.2.3 Mexico
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 Italy
    • 11.3.4 France
    • 11.3.5 Spain
    • 11.3.6 Rest of Europe
  • 11.4 Asia Pacific
    • 11.4.1 Japan
    • 11.4.2 China
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 New Zealand
    • 11.4.6 South Korea
    • 11.4.7 Rest of Asia Pacific
  • 11.5 South America
    • 11.5.1 Argentina
    • 11.5.2 Brazil
    • 11.5.3 Chile
    • 11.5.4 Rest of South America
  • 11.6 Middle East & Africa
    • 11.6.1 Saudi Arabia
    • 11.6.2 UAE
    • 11.6.3 Qatar
    • 11.6.4 South Africa
    • 11.6.5 Rest of Middle East & Africa

12 Key Developments

  • 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 12.2 Acquisitions & Mergers
  • 12.3 New Product Launch
  • 12.4 Expansions
  • 12.5 Other Key Strategies

13 Company Profiling

  • 13.1 Novadiscovery
  • 13.2 Dassault Systemes
  • 13.3 GNS Healthcare
  • 13.4 Clarivate
  • 13.5 Evotec
  • 13.6 Abzena Ltd.
  • 13.7 PerkinElmer Inc.
  • 13.8 Schrodinger, Inc.
  • 13.9 Selvita
  • 13.10 Tracxn Technologies
  • 13.11 WuXi AppTec
  • 13.12 Hoffmann- La Roche
  • 13.13 Mars
  • 13.14 PYC Therapeutics
  • 13.15 Immatics

List of Tables

  • Table 1 Global In Silico Clinical Trials Market Outlook, By Region (2022-2030) ($MN)
  • Table 2 Global In Silico Clinical Trials Market Outlook, By Type (2022-2030) ($MN)
  • Table 3 Global In Silico Clinical Trials Market Outlook, By Preclinical Trials (2022-2030) ($MN)
  • Table 4 Global In Silico Clinical Trials Market Outlook, By Clinical Trials (2022-2030) ($MN)
  • Table 5 Global In Silico Clinical Trials Market Outlook, By Post-Market Trials (2022-2030) ($MN)
  • Table 6 Global In Silico Clinical Trials Market Outlook, By Regulatory Compliance Trials (2022-2030) ($MN)
  • Table 7 Global In Silico Clinical Trials Market Outlook, By Disease Modeling Trials (2022-2030) ($MN)
  • Table 8 Global In Silico Clinical Trials Market Outlook, By Other Types (2022-2030) ($MN)
  • Table 9 Global In Silico Clinical Trials Market Outlook, By Simulation Type (2022-2030) ($MN)
  • Table 10 Global In Silico Clinical Trials Market Outlook, By Physiological Simulations (2022-2030) ($MN)
  • Table 11 Global In Silico Clinical Trials Market Outlook, By Toxicology Simulations (2022-2030) ($MN)
  • Table 12 Global In Silico Clinical Trials Market Outlook, By Disease Models (2022-2030) ($MN)
  • Table 13 Global In Silico Clinical Trials Market Outlook, By Population-Based Simulations (2022-2030) ($MN)
  • Table 14 Global In Silico Clinical Trials Market Outlook, By Virtual Patient Simulations (2022-2030) ($MN)
  • Table 15 Global In Silico Clinical Trials Market Outlook, By Therapeutic (2022-2030) ($MN)
  • Table 16 Global In Silico Clinical Trials Market Outlook, By Oncology (2022-2030) ($MN)
  • Table 17 Global In Silico Clinical Trials Market Outlook, By Infectious Disease (2022-2030) ($MN)
  • Table 18 Global In Silico Clinical Trials Market Outlook, By Cardiology (2022-2030) ($MN)
  • Table 19 Global In Silico Clinical Trials Market Outlook, By Neurology (2022-2030) ($MN)
  • Table 20 Global In Silico Clinical Trials Market Outlook, By Diabetes (2022-2030) ($MN)
  • Table 21 Global In Silico Clinical Trials Market Outlook, By Other Therapeutics (2022-2030) ($MN)
  • Table 22 Global In Silico Clinical Trials Market Outlook, By Technology (2022-2030) ($MN)
  • Table 23 Global In Silico Clinical Trials Market Outlook, By Computational Biology (2022-2030) ($MN)
  • Table 24 Global In Silico Clinical Trials Market Outlook, By Artificial Intelligence (2022-2030) ($MN)
  • Table 25 Global In Silico Clinical Trials Market Outlook, By Machine Learning (2022-2030) ($MN)
  • Table 26 Global In Silico Clinical Trials Market Outlook, By Systems Biology (2022-2030) ($MN)
  • Table 27 Global In Silico Clinical Trials Market Outlook, By Other Technologies (2022-2030) ($MN)
  • Table 28 Global In Silico Clinical Trials Market Outlook, By Application (2022-2030) ($MN)
  • Table 29 Global In Silico Clinical Trials Market Outlook, By Drug Discovery and Development (2022-2030) ($MN)
  • Table 30 Global In Silico Clinical Trials Market Outlook, By Medical Device Development (2022-2030) ($MN)
  • Table 31 Global In Silico Clinical Trials Market Outlook, By Digital Health Technologies (2022-2030) ($MN)
  • Table 32 Global In Silico Clinical Trials Market Outlook, By Personalized Medicine (2022-2030) ($MN)
  • Table 33 Global In Silico Clinical Trials Market Outlook, By Other Applications (2022-2030) ($MN)
  • Table 34 Global In Silico Clinical Trials Market Outlook, By End User (2022-2030) ($MN)
  • Table 35 Global In Silico Clinical Trials Market Outlook, By Pharmaceutical and Biotechnology Companies (2022-2030) ($MN)
  • Table 36 Global In Silico Clinical Trials Market Outlook, By Academic Institutions (2022-2030) ($MN)
  • Table 37 Global In Silico Clinical Trials Market Outlook, By Contract Research Organizations (CROs) (2022-2030) ($MN)
  • Table 38 Global In Silico Clinical Trials Market Outlook, By Regulatory Authorities (2022-2030) ($MN)
  • Table 39 Global In Silico Clinical Trials Market Outlook, By Other End Users (2022-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.